Robert D. Ciappenelli - 11 Jun 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role: Chief Commercial Officer
Signature: /s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 11 Jun 2021
Net transactions value: -$641,700
Form type: 4
Filing time: 15 Jun 2021, 19:19:11 UTC
Next filing: 14 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRNA	Common Stock	Options Exercise	$156,100	+10,000	+265%	$15.61	13,773	11 Jun 2021	Direct
transaction	DRNA	Common Stock	Sale	$350,000	-10,000	-73%	$35.00	3,773	11 Jun 2021	Direct	F1, F2
transaction	DRNA	Common Stock	Options Exercise	$312,200	+20,000	+530%	$15.61	23,773	14 Jun 2021	Direct
transaction	DRNA	Common Stock	Sale	$760,000	-20,000	-84%	$38.00	3,773	14 Jun 2021	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-10,000	-3.3%	$0.000000	290,000	11 Jun 2021	Common Stock	10,000	$15.61	Direct	F4
transaction	DRNA	Employee Stock Option (Right to Buy)	Options Exercise	$0	-20,000	-6.9%	$0.000000	270,000	14 Jun 2021	Common Stock	20,000	$15.61	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person sold an aggregate of 10,000 shares of Common Stock on June 11, 2021 (the "Shares Sold No. 1") as reported in this Form 4. The Shares Sold No. 1 represent 2.08% of 481,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 1 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F2	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020.
F3	The Reporting Person sold an aggregate of 20,000 shares of Common Stock on June 14, 2021 (the "Shares Sold No. 2") as reported in this Form 4. The Shares Sold No. 2 represent 4.24% of 471,298 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold No. 2 transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report.
F4	The option vests 25% on the first year anniversary of the vesting start date of June 3, 2019 and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date.